Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ANAB NASDAQ:IBRX NASDAQ:IDYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$37.71-1.2%$37.12$23.42▼$62.58$2.19B0.87844,455 shs502,787 shsANABAnaptysBio$20.33+1.0%$23.26$12.21▼$40.70$569.24M-0.19456,432 shs322,607 shsIBRXImmunityBio$2.34+0.4%$2.60$1.83▼$7.48$2.21B0.38.95 million shs5.62 million shsIDYAIDEAYA Biosciences$24.55-1.5%$23.26$13.45▼$40.25$2.15B0.12865,656 shs632,810 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%-2.81%+7.74%+15.57%-17.86%ANABAnaptysBio0.00%+0.54%-17.66%-7.00%-46.63%IBRXImmunityBio0.00%+1.30%-1.27%-12.36%-40.76%IDYAIDEAYA Biosciences0.00%-2.27%+1.15%+15.69%-37.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.4205 of 5 stars3.42.00.04.34.20.81.9ANABAnaptysBio1.9198 of 5 stars3.40.00.00.02.52.50.6IBRXImmunityBio2.158 of 5 stars3.61.00.00.02.51.70.6IDYAIDEAYA Biosciences4.4139 of 5 stars4.43.00.04.42.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.75Moderate Buy$56.3349.39% UpsideANABAnaptysBio 2.80Moderate Buy$46.13126.88% UpsideIBRXImmunityBio 3.20Buy$10.75359.40% UpsideIDYAIDEAYA Biosciences 2.75Moderate Buy$47.1091.85% UpsideCurrent Analyst Ratings BreakdownLatest ANAB, AGIO, IDYA, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.008/14/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.008/12/2025ANABAnaptysBioUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $20.008/7/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $45.008/5/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/28/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$71.00 ➝ $65.007/28/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$66.00 ➝ $72.007/25/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/24/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$42.00 ➝ $80.007/22/2025AGIOAgios PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$52.00 ➝ $51.007/22/2025IDYAIDEAYA BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M60.03N/AN/A$27.02 per share1.40ANABAnaptysBio$91.28M6.24N/AN/A$2.33 per share8.73IBRXImmunityBio$14.74M150.06N/AN/A($0.57) per share-4.11IDYAIDEAYA Biosciences$7M307.38N/AN/A$12.25 per share2.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.003.43N/AN/A1,590.42%-3.49%-3.23%10/30/2025 (Estimated)ANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)Latest ANAB, AGIO, IDYA, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 million7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74-$1.93-$0.19-$1.93$9.46 million$12.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AANABAnaptysBioN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.4814.04ANABAnaptysBioN/A8.228.22IBRXImmunityBioN/A4.113.98IDYAIDEAYA BiosciencesN/A12.3912.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AANABAnaptysBioN/AIBRXImmunityBio8.58%IDYAIDEAYA Biosciences98.29%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%ANABAnaptysBio33.50%IBRXImmunityBio76.79%IDYAIDEAYA Biosciences2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39058.10 million55.24 millionOptionableANABAnaptysBio10028.00 million18.62 millionOptionableIBRXImmunityBio590945.26 million219.39 millionOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableANAB, AGIO, IDYA, and IBRX HeadlinesRecent News About These CompaniesDAFNA Capital Management LLC Increases Stake in IDEAYA Biosciences, Inc. $IDYASeptember 1 at 7:14 AM | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by AnalystsSeptember 1 at 3:20 AM | marketbeat.comHsbc Holdings PLC Raises Holdings in IDEAYA Biosciences, Inc. $IDYAAugust 31 at 3:55 AM | marketbeat.comIDEAYA Biosciences, Inc. $IDYA Shares Acquired by Tema Etfs LLCAugust 30 at 8:19 AM | marketbeat.comIDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)August 29 at 10:11 PM | finanznachrichten.deIDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research CongressAugust 29 at 2:00 PM | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)August 29 at 6:00 AM | prnewswire.comIDEAYA Biosciences, Inc. $IDYA Shares Bought by Jump Financial LLCAugust 29 at 5:19 AM | marketbeat.comAlphaQuest LLC Boosts Stake in IDEAYA Biosciences, Inc. $IDYAAugust 29 at 4:57 AM | marketbeat.comPrice T Rowe Associates Inc. MD Reduces Stock Position in IDEAYA Biosciences, Inc. $IDYAAugust 29 at 4:06 AM | marketbeat.comNuveen LLC Acquires New Holdings in IDEAYA Biosciences, Inc. $IDYAAugust 29 at 3:36 AM | marketbeat.comVanguard Group Inc. Purchases 14,535 Shares of IDEAYA Biosciences, Inc. $IDYAAugust 26, 2025 | marketbeat.comIDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations EventsAugust 25, 2025 | prnewswire.comCandriam S.C.A. Trims Stock Position in IDEAYA Biosciences, Inc. $IDYAAugust 23, 2025 | marketbeat.comAberdeen Group plc Boosts Stock Holdings in IDEAYA Biosciences, Inc. $IDYAAugust 23, 2025 | marketbeat.comAlgert Global LLC Acquires Shares of 306,708 IDEAYA Biosciences, Inc. $IDYAAugust 21, 2025 | marketbeat.comIDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025August 18, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Deutsche Bank AGAugust 17, 2025 | marketbeat.comRBC Capital Remains a Buy on IDEAYA Biosciences (IDYA)August 11, 2025 | theglobeandmail.comLeerink Partnrs Has Bullish Estimate for IDYA Q3 EarningsAugust 11, 2025 | marketbeat.comFY2025 EPS Estimates for IDYA Cut by Cantor FitzgeraldAugust 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANAB, AGIO, IDYA, and IBRX Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$37.71 -0.47 (-1.23%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$37.72 +0.02 (+0.04%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.AnaptysBio NASDAQ:ANAB$20.33 +0.20 (+0.99%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$19.85 -0.48 (-2.36%) As of 08/29/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.ImmunityBio NASDAQ:IBRX$2.34 +0.01 (+0.43%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.35 +0.01 (+0.21%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.IDEAYA Biosciences NASDAQ:IDYA$24.55 -0.38 (-1.52%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$24.47 -0.08 (-0.33%) As of 08/29/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
